Amgen to Buy Celgene Drug for $13.4 Billion, Sustainability Chemists, Trump’s Plan to Force Companies From China

Rebecca Spalding, Bloomberg News Biotech Reporter, discusses Amgen paying $13.4 billion for a blockbuster psoriasis drug from Celgene, which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb. Aidan Mouat, CEO at Hazel Technologies, shares the solution he’s created to combat food waste. Shawn Donnan, Bloomberg News Senior Trade Reporter, explains what White House officials have to say about President Trump’s authority to force American companies to leave China. Bloomberg Businessweek Editor Joel Weber and Bloomberg Businessweek Politics Editor Jillian Goodman break down the problem with Democratic health-care proposals. And we Drive to the Close with Hilary Kramer, President and CIO at A&G Capital. 

Hosts: Carol Massar and Jason Kelly. Producer: Paul Brennan. 

See omnystudio.com/listener for privacy information.